Company profile
UK company SC363190, incorporated on 28 July 2009.
Home page - Medannex
Medannex is an award-winning clinical-stage Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1. MDX-124 could provide a new treatment option as a single agent or in combination with established cancer therapies, and clinical trials are now eagerly anticipated. Professor Daniel Palmer,Department of Molecular & Clinical Cancer Medicine,University of Liverpool Our goal
Company number SC363190
Financial period: 1 Oct 2023 to 30 Sep 2024
Reference milestones and recent Companies House filing stream events.
RESOLUTIONS | Transaction WUY4ODNHMkFhZGlxemtjeA | Paper/PDF filed
Published 17 Aug 2026 22:44
CS01 | Transaction MzUzODMxMzE3MmFkaXF6a2N4
Published 12 Aug 2026 13:46
SH01 | Transaction MzUzODAxNTU4NmFkaXF6a2N4
Published 11 Aug 2026 12:26
Company registered at Companies House
This company has been established to further develop Annnexin-A1 antibodies as novel immunosuppressant.
N/A
1 Aug 2024 to 28 Feb 2026
Annexin-A1 is a protein that is overproduced by many tumours and plays a key role in various cancer-related processes including tumour growth, angiogenesis, drug resistance and metastasis. Medannex has generated an antibody (MDX-124) that specifically targets and blocks the cancer promoting activity of annexin-A1\. This project is a vital step in the deve...
1 Dec 2019 to 28 Feb 2021
‘MedAnnex is developing a novel oncology therapy based on targeting a protein known as annexin-A1, which is thought to play a role in the development of cancer. This project is a vital step in the development of an innovative cancer therapy with the potential to become a major new drug to improve patient quality of life and extend lives.’
1 Jan 2019 to 31 Jul 2020
MedAnnex is developing a new therapeutic called annexuzlimab(tm). It targets and binds to annexin-A1, a protein that occurs naturally in the human body and plays an important role in the response of the immune system to inflammation. There are well known links between inflammation and numerous major diseases including several autoimmune conditions such as...
